Abstract Details

Title Clinical Safety of the Novel, Selective S1P Receptor Modulator, Ozanimod, from Phase 2 Trials in Relapsing Multiple Sclerosis (RADIANCE) and Moderate to Severe Ulcerative Colitis (TOUCHSTONE)

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 092

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Paul Frohna, MD, PhD, PharmD (Bioniz Therapeutics, Inc) PRESENTER	No disclosure on file
Allan Olson, MD (Receptos, Inc.)	No disclosure on file
Matthew W. Cravets	No disclosure on file
Jeffrey Hartung, PhD (Receptos, Inc.)	No disclosure on file
	No disclosure on file
	No disclosure on file
Sheila Gujrathi (Receptos)	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��